Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Masoud Tavazoie

Chief Executive Officer & Co-founder

Dr. Tavazoie is co-founder, Board Director, and Chief Executive Officer of Rgenix. A physician-scientist by training, he has 15 years of experience spanning the fields of pharmacology, oncology, and small-RNA biology. He is co-inventor on multiple patents related to both small-molecule and biologic therapeutics in oncology and was instrumental in the development of the Rgenix drug discovery platform.

Dr. Tavazoie received his undergraduate degree in Molecular and Cell Biology from the University of California, Berkeley, and his M.D. and Ph.D. degrees from the College of Physicians & Surgeons at Columbia University. Following an internship in Internal Medicine, he completed clinical training in Dermatology at NYU, where he was later appointed as the Marion Sulzberger Research Fellow with a focus on discovery and development of novel immuno-therapeutic approaches to the treatment of melanoma and other solid tumors. He has authored publications in leading journals such as Nature, Cell Stem Cell, Nature Neuroscience, and Neuron. Among his awards are the NIH Medical Scientist Training Program Fellowship, the Brunie Neural Stem Cell Award, and the Lowenfish Prize for creative research in Dermatology